Top

Acta Neurologica Belgica

Published in:

09-10-2023 | Parkinson's Disease | Original article

LncRNA MEG8 ameliorates Parkinson’s disease neuro-inflammation through miR-485-3p/FBXO45 axis

Authors: Xia Lin, Taotao Tao, Xinwei He, Lingqun Mao, Luping Pan, Linkao Chen

Published in: Acta Neurologica Belgica | Issue 2/2024

Abstract

Objective

Studies suggest that LncRNA maternally expressed 8, small nucleolar RNA host gene (MEG8) contributes to inflammatory regulation, while the function and potential mechanisms of MEG8 in Parkinson’s disease (PD) are unknown. This study aimed to assess the clinical value and biological function of MEG8 in PD.

Methods

One hundred and two PD patients, eighty-six AD patients, and eighty healthy controls were enrolled in this study. Lipopolysaccharide (LPS)-induced microglia BV2 constructs an in vitro cell model. RT-qPCR was conducted to quantify the levels of MEG8, miR-485-3p, and FBXO45 in serum and cells. ROC curve was employed to examine the diagnostic value of MEG8 in PD. Serum and cellular pro-inflammatory factor secretion were quantified by ELISA. Dual-luciferase reporter and RIP assay to validate the targeting relationship between miR-485-3p and FBXO45.

Results

MEG8 and FBXO45 were significantly decreased in the serum of PD patients and LPS-induced bv2, while miR-485-3p was increased (P < 0.05). ROC curve confirmed that serum MEG8 has high sensitivity and specificity to identify PD patients from healthy controls and AD patients, respectively. Elevated MEG8 alleviated LPS-induced inflammatory factor overproduction compared with LPS-induced BV2 (P < 0.05), but this alleviating effect was eliminated by miR-485-3p (P < 0.05). The LPS-induced inflammatory response was suppressed by the low expression of miR-485-3p but significantly reversed by silencing of FBXO45. MEG8 was a sponge for miR-485-3p and inhibited its levels and promoted FBXO45 expression (P < 0.05).

Conclusion

Elevated MEG8 is a potential diagnostic biomarker for PD and may mitigate inflammatory damage in PD via the miR-485-3p/FBXO45 axis.

Available only for authorised users

Geng X, Zou Y, Li S, Qi R, Yu H, Li J (2023) MALAT1 mediates alpha-synuclein expression through miR-23b-3p to induce autophagic impairment and the inflammatory response in microglia to promote apoptosis in dopaminergic neuronal cells. Mediators Inflamm 2023:4477492CrossRefPubMedPubMedCentral

Asadi MR, Abed S, Kouchakali G, Fattahi F, Sabaie H, Moslehian MS et al (2023) Competing endogenous RNA (ceRNA) networks in Parkinson’s disease: a systematic review. Front Cell Neurosci 17:1044634CrossRefPubMedPubMedCentral

Varma P, Narayan L, Alty J, Painter V, Padmakumar C (2021) An innovative personalised management program for older adults with Parkinson’s disease: new concepts and future directions. J Pers Med. 11:1CrossRef

Peng S, Jia J, Sun J, Xie Q, Zhang X, Deng Y et al (2019) LXW7 attenuates inflammation via suppressing Akt/nuclear factor kappa B and mitogen-activated protein kinases signaling pathways in lipopolysaccharide-stimulated BV2 microglial cells. Int Immunopharmacol 77:105963CrossRefPubMed

Kuo MC, Liu SC, Hsu YF, Wu RM (2021) The role of noncoding RNAs in Parkinson’s disease: biomarkers and associations with pathogenic pathways. J Biomed Sci 28(1):78CrossRefPubMedPubMedCentral

Liu L, Zhou T, Li T, Liang Z, Luo X (2022) LncRNA DLX6-AS1 promotes microglial inflammatory response in Parkinson’s disease by regulating the miR-223-3p/NRP1 axis. Behav Brain Res 431:113923CrossRefPubMed

Abrishamdar M, Jalali MS, Rashno M (2022) MALAT1 lncRNA and Parkinson’s disease: the role in the pathophysiology and significance for diagnostic and therapeutic approaches. Mol Neurobiol 59(9):5253–5262CrossRefPubMed

Li K, Wang Z (2023) lncRNA NEAT1: key player in neurodegenerative diseases. Ageing Res Rev 86:101878CrossRefPubMed

Li YZ, Zhu HC, Du Y, Zhao HC, Wang L (2022) Silencing lncRNA SLC16A1-AS1 induced ferroptosis in renal cell carcinoma through miR-143-3p/SLC7A11 signaling. Technol Cancer Res Treat 21:15330338221077804CrossRefPubMedPubMedCentral

10.

Lin X, Wang R, Li R, Tao T, Zhang D, Qi Y (2022) Diagnostic performance of miR-485-3p in patients with Parkinson’s disease and its relationship with neuroinflammation. Neuromolecular Med 24(2):195–201CrossRefPubMed

11.

Xie W, Jiang L, Huang X, Shang H, Gao M, You W et al (2021) lncRNA MEG8 is downregulated in osteoarthritis and regulates chondrocyte cell proliferation, apoptosis and inflammation. Exp Ther Med 22(4):1153CrossRefPubMedPubMedCentral

12.

Xu D, Dai R, Chi H, Ge W, Rong J (2021) Long non-coding RNA MEG8 suppresses hypoxia-induced excessive proliferation, migration and inflammation of vascular smooth muscle cells by regulation of the miR-195-5p/RECK axis. Front Mol Biosci 8:697273CrossRefPubMedPubMedCentral

13.

Buccarelli M, Lulli V, Giuliani A, Signore M, Martini M, D’Alessandris QG et al (2020) Deregulated expression of the imprinted DLK1-DIO3 region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3. Neuro Oncol 22(12):1771–1784CrossRefPubMedPubMedCentral

14.

Tan MC, Widagdo J, Chau YQ, Zhu T, Wong JJ, Cheung A et al (2017) The activity-induced long non-coding RNA Meg3 modulates AMPA receptor surface expression in primary cortical neurons. Front Cell Neurosci 11:124CrossRefPubMedPubMedCentral

15.

Zhao XY, Lu MH, Yuan DJ, Xu DE, Yao PP, Ji WL et al (2019) Mitochondrial dysfunction in neural injury. Front Neurosci 13:30CrossRefPubMedPubMedCentral

16.

Sui S, Sun L, Zhang W, Li J, Han J, Zheng J et al (2021) LncRNA MEG8 attenuates cerebral ischemia after ischemic stroke through targeting miR-130a-5p/VEGFA signaling. Cell Mol Neurobiol 41(6):1311–1324CrossRefPubMed

17.

Zheng Y, Sun S, Yu M, Fu X (2019) Identification of potential hub-lncRNAs in ischemic stroke based on Subpathway-LNCE method. J Cell Biochem 120(8):12832–12842CrossRefPubMed

18.

Daniel SE, Lees AJ (1993) Parkinson’s disease society brain bank, London: overview and research. J Neural Transm Suppl 39:165–172PubMed

19.

Zhang J, Yang Y, Zhou C, Zhu R, Xiao X, Zhou B et al (2022) LncRNA miR-17-92a-1 cluster host gene (MIR17HG) promotes neuronal damage and microglial activation by targeting the microRNA-153-3p/alpha-synuclein axis in Parkinson’s disease. Bioengineered 13(2):4493–4516CrossRefPubMedPubMedCentral

20.

Zhu Z, Huang P, Sun R, Li X, Li W, Gong W (2022) A Novel long-noncoding RNA LncZFAS1 prevents MPP(+)-induced neuroinflammation through MIB1 activation. Mol Neurobiol 59(2):778–799CrossRefPubMed

21.

Zhu HB, Li B, Guo J, Miao YZ, Shen YT, Zhang YZ et al (2021) LncRNA MEG8 promotes TNF-alpha expression by sponging miR-454-3p in bone-invasive pituitary adenomas. Aging (Albany NY) 13(10):14342–14354CrossRefPubMed

22.

Tolosa E, Garrido A, Scholz SW, Poewe W (2021) Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol 20(5):385–397CrossRefPubMedPubMedCentral

23.

Lotankar S, Prabhavalkar KS, Bhatt LK (2017) Biomarkers for Parkinson’s disease: recent advancement. Neurosci Bull 33(5):585–597CrossRefPubMedPubMedCentral

24.

Zhou Y, Zhao Z, Yan L, Yang J (2021) MiR-485-3p promotes proliferation of osteoarthritis chondrocytes and inhibits apoptosis via Notch2 and the NF-kappaB pathway. Immunopharmacol Immunotoxicol 43(3):370–379CrossRefPubMed

25.

Sole C, Domingo S, Ferrer B, Moline T, Ordi-Ros J, Cortes-Hernandez J (2019) MicroRNA expression profiling identifies miR-31 and miR-485-3p as regulators in the pathogenesis of discoid cutaneous lupus. J Invest Dermatol 139(1):51–61CrossRefPubMed

26.

Koh HS, Lee S, Lee HJ, Min JW, Iwatsubo T, Teunissen CE et al (2021) Targeting microRNA-485-3p blocks Alzheimer’s disease progression. Int J Mol Sci 22(23):13136CrossRefPubMedPubMedCentral

27.

Tsai M, Osman W, Adair J, ElMergawy R, Chafin L, Johns F et al (2022) The E3 ligase subunit FBXO45 binds the interferon-lambda receptor and promotes its degradation during influenza virus infection. J Biol Chem 298(12):102698CrossRefPubMedPubMedCentral

28.

Saiga T, Fukuda T, Matsumoto M, Tada H, Okano HJ, Okano H et al (2009) Fbxo45 forms a novel ubiquitin ligase complex and is required for neuronal development. Mol Cell Biol 29(13):3529–3543CrossRefPubMedPubMedCentral

29.

Tada H, Okano HJ, Takagi H, Shibata S, Yao I, Matsumoto M et al (2010) Fbxo45, a novel ubiquitin ligase, regulates synaptic activity. J Biol Chem 285(6):3840–3849CrossRefPubMed

30.

Na Y, Calvo-Jimenez E, Kon E, Cao H, Jossin Y, Cooper JA (2020) Fbxo45 binds SPRY motifs in the extracellular domain of N-cadherin and regulates neuron migration during brain development. Mol Cell Biol 40(14):e00539-e619CrossRefPubMedPubMedCentral

31.

Cao T, Cui Y, Wang Y, Wu L, Yu K, Chen K et al (2022) CACNA1C-AS2 inhibits cell proliferation and suppresses cell migration and invasion via targeting FBXO45 and PI3K/AKT/mTOR pathways in glioma. Apoptosis 27(11–12):979–991CrossRefPubMed

Title: LncRNA MEG8 ameliorates Parkinson’s disease neuro-inflammation through miR-485-3p/FBXO45 axis
Authors: Xia Lin
Taotao Tao
Xinwei He
Lingqun Mao
Luping Pan
Linkao Chen
Publication date: 09-10-2023
Publisher: Springer International Publishing
Keyword: Parkinson's Disease
Published in: Acta Neurologica Belgica / Issue 2/2024
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-023-02388-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

LncRNA MEG8 ameliorates Parkinson’s disease neuro-inflammation through miR-485-3p/FBXO45 axis

Abstract

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2024

Paroxysmal hemidystonia as the initial presentation of multiple sclerosis: an illustrative video depicting hyperventilation-triggered dystonia

Causal effects of genetically predicted testosterone on Alzheimer’s disease: a two-sample mendelian randomization study

Perioperative management of dural sinus malformation and high-flow arteriovenous fistula in an infant

More than grey matter: a case of spinocerebellar ataxia type 48

Post-stroke Chinese pure alexia: linguistic features and neuropsychological profiles

Prognostic factors for falls in Parkinson’s disease: a systematic review